



Apotekarsocieteten

17th Symposium on Pharmacokinetics and Drug Metabolism

12-13 November 2024



Program

Tuesday 12 th November	
11.30 – 12.00	Registration
12.00 – 13.00	Lunch
13.00 – 13.10	Opening and introduction of meeting Suzanne Iverson Hemberg, Toxicology Knowledge Team Sweden, Rasmus Jansson Löfmark, AstraZeneca
13.10 – 14.40	Session 1: Biotransformation and impact of drug metabolites Chairs: Johanna Haglund, MetaSafe, Johan Bylund, CTC, Clinical Trial Consultants Speakers: 13.10 – 13.40 • "Unusual" Biotransformation Reactions of Drugs and Drug Candidates, Emre Isin, Servier 13.40 – 14.10 • Drug metabolism in drug discovery-PK, PD and safety aspects, Carl Petersson, Merck Healthcare 14.10 – 14.40 • Structural elucidation of conjugation drug metabolites by utilizing novel electron-activated dissociation (EAD), Ferran Sánchez, SCIEX
14.40 – 15.20	Break & coffee
15.20 – 17.00	Session 2: Drug Transporter considerations across drug modalities Chairs: Anna Nordmark, Nordmark ClinPharm consulting, Rasmus Jansson-Löfmark, AstraZeneca Speakers: 15.20-15.45 • Drug transporters and large molecules, Pär Matsson, Gothenburg University 15.45-16.10 • Antibody Brain Exposure and Distribution Using Passive or Active Transport Mechanisms to Target Brain Diseases, Sofia Gustafsson, BioArctic 16.10-16.35 • Translational aspects of oxycodone brain delivery via the proton-coupled organic cation (H ⁺ /OC) antiporter system: the journey from cells to pigs. Irena Loryan, Translational Pharmacokinetics/Pharmacodynamics group, Dep of Pharmacy Uppsala University 16.35-17.00 • Use of endogenous biomarkers for evaluating transporter-mediated DDIs (tDDI) – Case studies from AstraZeneca, Vijender Panduga, AstraZeneca
17.00 – 17.15	Break
17.15 – 18.00	Candlelight lecture: At the Intersection of Science and Entrepreneurship – My CRO journey Chair: Rasmus Jansson-Löfmark, AstraZeneca Speaker: Bengt Dahlström, PhD, Associate Professor Bengt Dahlström is Associate Professor in Pharmacokinetics and Drug Therapy from Uppsala University, Sweden and has published over 50 scientific papers in this area. He is an expert in pharmacokinetics, drug research and development with over 40 years' experience from leading positions in Pharmaceutical companies and CROs. He is co-founder of leading Clinical Research Organizations: CTC AB, PMC AB, MiniDoc AB and AB Biopharmacon.
18.00 – 18.45	Poster session with refreshments Chair: Alan Faraj, Novo Nordisk
19.00 – 23.00	Dinner

Wednesday 13th November

<p>08.30 – 10.15</p> <p>08.35-09.00</p> <p>09.00-09.25</p> <p>09.25-09.50</p> <p>09.50-10.15</p>	<p>Session 3: Pharmacokinetic and pharmacodynamic considerations in rare disease and special populations</p> <p>Chairs: Anna Nordmark, Nordmark ClinPharm Consulting, Mia Lundblad, Novo Nordisk, Angelica Quartino, AstraZeneca</p> <p>Speakers:</p> <ul style="list-style-type: none"> • Physiologically based pharmacokinetic modelling and simulation in perinatal populations: opportunities, challenges and case examples, Pieter Annaert, Drug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium • PBPK simulations in special populations. Are we ready for prime time? Eva Berglund, Certara Drug Development Services • Clinical Pharmacology considerations for development of somapacitan for rare pediatric growth disorders, Rasmus Juul Kildemoes, Clinical Pharmacology RD&AT, Novo Nordisk • Model-informed development of Mim8 – a novel bispecific antibody for the treatment of haemophilia A, Mads Kreilgaard, Pharmacometrics, Novo Nordisk
<p>10.15 – 10.45</p>	<p>Break & coffee</p>
<p>10.45 – 12.15</p> <p>10.45-11.15</p> <p>11.15-11.45</p> <p>11.45-12.15</p>	<p>Session 4: Bridging strategies for drug-device products</p> <p>Chairs: Markus Fridén, AstraZeneca, Mia Lundblad, Novo Nordisk</p> <p>Speakers:</p> <ul style="list-style-type: none"> • Ambition Zero Carbon: Accelerating adoption of Next Generation Propellant inhalation sprays by linking propellant and aerosol physics to predicted lung efficacy, Duy Nguyen & Michael Williams, AstraZeneca • Improved bioequivalence assessment through model-informed and model-based strategies, Xiaomei Chen, Uppsala University • Biopharmaceutical Evaluation of the Subcutaneous Administration, Marta Venczel, Sanofi
<p>12.15 – 13.15</p>	<p>Lunch</p>
<p>13.15 – 13.45</p>	<p>Rosenön Award</p> <p>Chair: Suzanne Iverson, Toxicology Knowledge Team Sweden</p> <p>Award winner: Luna Prieto Garcia, AstraZeneca</p>
<p>13.45 – 14.45</p> <p>13.45-14.15</p> <p>14.15-14.45</p>	<p>Session 5: Pharmacokinetics-Pharmacodynamics of drug combination therapies</p> <p>Chairs: Markus Fridén, AstraZeneca, Angelica Quartino, AstraZeneca</p> <p>Speakers:</p> <ul style="list-style-type: none"> • Development of a pre-clinical model-based drug regimen platform for antibiotics within a European perspective, Ulrika Simonsson, Uppsala University • Using Translational PKPD to narrow down the parameter space to explore dose and schedule in the clinic of anti-cancer agents, Owen Jones, AstraZeneca
<p>14.45 – 15.00</p>	<p>Closure of meeting</p>

